Navigation Links
New Protocols for Isolating High- Molecular-Weight Genomic DNA


Rapidly recover intact DNA from blood, bone marrow, and cultured cells

Brenda J. Rogers Mark J. Dycaico
Stratagene

Stratagene now offers updated protocols to isolate and purify high-molecular-weight genomic DNA using the RecoverEase DNA isolation kit. New procedures include DNA isolation from blood, bone marrow, and tissue culture cells. In addition, protocols for liver, lung, kidney, spleen, testes, and brain are also included. Each procedure eliminates the need for toxic phenol or chloroform and requires very little hands-on time to perform. Use the kit to minimize physical manipulation of the DNA the point in purification methodology where DNA is most susceptible to shearing forces. Fully hydrated high-molecular-weight DNA is ready to use in molecular biological applications in less than 24 hours.

The RecoverEase DNA isolation kit is designed to isolate very high-molecular-weight genomic DNA by reducing the shearing forces that take place in traditional methods using phenol-chloroform extraction and ethanol precipitation. The basic kit procedure requires tissue homogenization, filtration through a filter unit supplied with the kit to remove cellular debris (<3 minutes), isolation of the cell nuclei by centrifugation (<20 minutes), and protease digestion of the nuclei (45 minutes).1,2 The resulting suspension is transferred to a free-floating RecoverEase kit cup where the digested proteins and low molecular weight contaminants are removed by dialysis (16 to 48 hours), leaving behind fully hydrated DNA, which is ready for immediate use. From previous experiments using field inversion analysis, DNA isolated in this way, produced products that were 500-kb long.2 Subsequent Southern blot analysis demonstrated that the DNA cut with a variety of restriction enzymes (data not shown). These benefits, along with higher packaging efficiencies, make the RecoverEase DNA isolation kit the recommended method for purifying high-molecular-weight genomic DNA from blood, bone marrow, and cultured cells.

Big Blue Transgenic Rodent Mutation Assay and Cell Culture System

Genomic DNA isolated with this kit is ideal for recovering lambda shuttle vectors in transgenic in vivo mutation assay systems, such as Stratagenes Big Blue mutation assay systems.*,3,4,5 An important step in these mutation assays is retrieving large quantities of shuttle vector from the animals genomic DNA for subsequent analysis of mutations within a target region of the vector. The shuttle vector in Big Blue was derived from bacteriophage lambda and can be retrieved from the animal by subjecting the genomic DNA to the specialized in vitro lambda Transpack packaging extract.**,4 Because the shuttle vector is nearly 50-kb long and is present in multiple copies within the genome of the animal, efficient packaging is contingent on genomic DNA preparations of very high-molecular weight.6 The DNA must also have sufficient purity so as to be free of substances that inhibit the packaging reaction. For these reasons, measuring packaging efficiency in DNA preparations made from shuttle vector transgenics is a good indicator of DNA size and purity. DNA yielded from using the kit averaged a 74% greater recovery of plaque-forming units (pfu) per Transpack packaging reaction over organic extracted DNA overall for liver, kidney, spleen, testes, lung, and brain in Big Blue transgenic mice.6

RecoverEase DNA Isolation Kit vs. Organic Extraction

The RecoverEase method (see Methods) was compared with the organic extraction technique in relation to DNA yield, quality, and packaging efficiency. The latter technique was taken from Stratagenes Big Blue DNA isolation kit, which uses a modified phenol-chloroform extraction and an ethanol precipitation protocol optimized for isolating high-molecular-weight genomic DNA from transgenic animals containing lambda shuttle vectors. The Big Blue DNA isolation kit was the first kit specifically designed to prepare genomic DNA of size and quality that, when subjected to in vitro packaging extracts, yielded large numbers of rescued shuttle vector.

Table 1
Average Lambda Phage Recovery with RecoverEase DNA Isolation Kit and Organic Extraction Methods

Tissue

Tissue source

Method

Average yieldb

Average pfu/reactionc

Average total pfu recoverabled

Average pfu/mg DNAe

Blood

Big Blue rats

Dialysis
(RecoverEase kit)

45 mg

226,000

3,892,000

86,000

Organic Extraction

NRf

NR

NR

NR

Bone marrow

Big Blue mice

Dialysis
(RecoverEase kit)

180 mg

898,000

29,126,000

162,000

Organic Extraction

150 mg

798,000

7,477,000

50,000

Big Blue rats

Dialysis
(RecoverEase kit)

76 mg

200,000

5,884,000

77,000

Organic Extraction

100 mg

122,000

1, 148,000

11,000

Fibroblast
(cultured cells)

Big Blue mice

Dialysis
(RecoverEase kit)

138 mg

702,000

28,417,000

206,000

Organic Extraction

102 mg

636,000

5,959,000

58,000

Big Blue
Rat 2

Dialysis
(RecoverEase kit)

96 mg

486,000

15,551,000

162,000

Organic Extraction

86 mg

419,000

3,929,000

46,000

Overall averageg

Dialysis
(RecoverEase kit)

122 mg

572,000

19,744,000

152,000

Organic Extraction

110 mg

494,000

4,628,000

41,000

a Results are the averages of 2 to 5 samples each.

bAn aliquot of the recovered DNA was sheared through an 18-gauge needle, and the optical density at 260 nm was used to determine the DNA concentration for each sample. The concentration was multiplied by the volume recovered to give the DNA yield.

cDNA (8 l) was packaged per the Transpack protocol, and an aliquot of the total DNA was plated on the Big Blue SCS-8 E. coli strain to determine the number of pfu per reaction.

dThe estimated total pfu recoverable was determined using the number of pfu per reaction multiplied by the number of estimated reactions achievable from the total volume of DNA recovered.

eThe pfu/ug DNA was determined by dividing the total recoverable pfu by the total yield of DNA.

fNR: none recovered.

g The average of all samples for mice, rats, and tissues combined (for each extraction technique). For comparison purposes, average values are for bone marrow and fibroblast only.

Blood samples were collected from Big Blue rats, while individual bone marrow samples were taken from both Big Blue mice and Big Blue rats. The Big Blue mouse embryonic fibroblast and Big Blue rat 2 embryonic fibroblast cell lines were also tested. Genomic DNA was isolated from two to five individual samples of each tissue type, using both dialysis and organic extraction methods. The results of the comparison are shown in Table 1. When using 5 to 7 ml of rat blood, the standard organic extraction protocol (Big Blue DNA isolation kit) failed to yield DNA, even after two attempts. However, other organic extraction protocols begin with a blood volume of 20 ml7 so the lack of DNA recovery may have been due to an insufficient starting blood volume. The dialysis method yielded enough high-molecular-weight DNA from the same blood volume (5 to 7 ml) to package an average of over 3 million pfu of shuttle vector per sample. Among the remaining tissues tested, packaging efficiencies averaged 16% higher with the RecoverEase DNA samples, compared to those prepared using organic extraction. Although this increase is modest compared to previous comparisons in tissues such as liver,6 note that bone marrow and cultured cells are among the best substrates for the organic extraction method in terms of high rates of packaging success. DNA yields were similar using both techniques. DNA purity was also indistinguishable, with A260/280 ratios of 1.8 among all samples (data not shown).

Conclusions

The list of tissues amenable to Stratagenes RecoverEase DNA isolation kit now includes blood, bone marrow, and cultured cell lines. With the kit, reduce the need for hands-on time, eliminate toxic organic solutions, and remove ethanol precipitation and lengthy rehydration steps. Other potential applications for genomic DNA recovery include Southern blot analysis, pulsed-field gel electrophoresis, PCR amplification, genomic library preparation, and shuttle vector recovery in transgenic in vivo mutation assays.

Methods8

Blood: Recover rodent whole blood (5 to 7 ml) with the anticoagulant ACD (0.48% citric acid w/v, 1.32% sodium citrate w/v, 1.47% glucose w/v),7 and add five volumes of Tris-buffered ammonium chloride (140 mM NH4Cl, 17 mM Tris-HCl, pH 7.65). After 5 minutes at 37C, pellet the lysed blood cells by centrifugation, then wash the pellet with NaCl (0.85%) solution.7 The pellet may be stored at 80C. When ready for use, thaw the pellet, and isolate and purify the DNA following the standard kit protocol.

Bone Marrow: Inject lysis buffer through two mouse femurs or one rat femur, and incubate the lysate on ice for 10 minutes; centrifuge and digest/dialyze per the standard kit protocol.

Cultured Cells: Suspend cells (1 to 5 x 106) in lysis buffer, eliminate the coarse disruption step, and follow the standard procedure.

REFERENCES
  1. Monforte, J.A., et al. (1995) Environ. Mol. Mutagen. 23 (Suppl. 23): 46.

  2. Rogers B.J., et al. (1996) Environ. Mol. Mutagen. 27 (Suppl. 27): 57.

  3. Short, J.M., et al. (1988) Fed. Proc. 8515a.

  4. Kohler, S.W., et al., (1991) Proc. Natl. Acad. Sci. USA 88: 7958-7962.

  5. Jakubczak, J.L., et al., (1996) Proc. Natl. Acad. Sci. USA 93: 9073-9078.

  6. Rogers, B.J., et al. (1996) Strategies 9 3: 73-74.

  7. Sambrook, J., et al. (1987) Molecular Cloning: A laboratory Manual,Second edition. Cold Spring Harbor Press. New York. p. 9.17.

  8. Rogers, B.J., (1998) Environ. Mol. Mutagen. 31 (Suppl. 29): 12.

* U.S. Patent Nos. 5,347,075 and 5,824,287 and 5,589,155; European Patent No. 0289121;Japanese Patent No. 2618973
** U.S. Patent No. 5,188,957


'"/>

Source:


Page: All 1 2 3 4 5 6 7 8

Related biology technology :

1. Eppendorf Multiporator Transfection Protocols for Eukaryotic Cells
2. Eppendorf Multiporator Transfection Protocols for Eukaryotic Cells
3. Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler
4. High-Level Expression of Peanut Allergens Affected by Rare Codon Usage
5. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
6. Highest Possible Transformation Efficiencies for High-Throughput Applications
7. High-Throughput Cultivation of Bacterial Clones
8. Safe Production of High-Titer Retrovirus
9. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
10. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
11. pfuturbo DNA Polymerase: A High-Performance, High-Fidelity Enzyme Ideal for PCR Cloning

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Protocols for Isolating High Molecular Weight Genomic DNA

(Date:12/1/2009)... , SARASOTA, Fla., Dec. 1 ...s, Osprey Biotechnics Inc. of Sarasota has appoint...tributor. ,, Lake is located near Birmingham, ...ial bacteria which serve the agricultural, waste w...bred to be hungry and to open drain fields, and cl...
(Date:12/1/2009)... EpiVax, Inc. today announce...IX: RO, ROG; OTCQX: RHHBY) aimed at evaluating Epi...h could potentially reduce detrimental immune resp...-EpiVax collaboration, the EpiVax Tregitope techno...nogenicity of protein therapeutics. , ...
(Date:12/1/2009)... , HUNTINGTON BEACH, California and...world leader in molecular cancer diagnostics, anno... Medicare administrator, has established,coding gu...rint is Agendia,s,FDA-cleared breast cancer recurr...ce 2008. , Patients across the United Sta...
(Date:12/1/2009)... , NEW YORK and MONTREAL, Dec. 1 /PRNewswire-...rtner -ICBS Ltd. (OTCPK: ICBT), announced today th...; Manufacturing Inc., of Canada for the manufactur...istribution in the U.S. ,, "We have seen the di...n fresh vegetables and packaged salads in the past...
Breaking Biology Technology:EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 2EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 3Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R) 2
...Net Revenues Up 98% and Adjusted EBITDA Up 70% Yea...ewswire/ -- WuXi PharmaTech,(Cayman) Inc. (NYSE: ...medical device research and development outsourcin...States, today announced its unaudited financial,re...08. During the quarter,WuXi,s net revenue increase...
...er Revenue Increases by 45% From Prior Year ...0 - Six Month Revenue Increases by 37% Fr... Income of $786,000, SAN DIEGO, Nov. 12 Imagenet...y results for its second fiscal quarter,and six mo...r the quarter,were $2,656,000 an increase of 45% f...
...eden, November 12 Cellectricon, a leading,provide...ry, has today,received its most significant and la...ee Cellaxess(R)HT systems and the customer is a le...de proves the system,s unique features and,value, ...te-of-the-art,products for drug discovery and rese...
Other Biology Technology:WuXi PharmaTech Announces Third Quarter 2008 Results 2WuXi PharmaTech Announces Third Quarter 2008 Results 3WuXi PharmaTech Announces Third Quarter 2008 Results 4WuXi PharmaTech Announces Third Quarter 2008 Results 5WuXi PharmaTech Announces Third Quarter 2008 Results 6WuXi PharmaTech Announces Third Quarter 2008 Results 7WuXi PharmaTech Announces Third Quarter 2008 Results 8WuXi PharmaTech Announces Third Quarter 2008 Results 9WuXi PharmaTech Announces Third Quarter 2008 Results 10WuXi PharmaTech Announces Third Quarter 2008 Results 11WuXi PharmaTech Announces Third Quarter 2008 Results 12WuXi PharmaTech Announces Third Quarter 2008 Results 13Imagenetix, Inc. Reports Second Quarter and Six Month Results 2Imagenetix, Inc. Reports Second Quarter and Six Month Results 3Imagenetix, Inc. Reports Second Quarter and Six Month Results 4Cellectricon Receives Milestone Order for Cellaxess(R)HT, the World's First High Throughput RNAi Screening System 2
(Date:11/30/2009)... , A team of scientists from The Forsyth Institut...e CDC and the Wadsworth Center, have used state-of...hitecture of Treponema pallidum, the bacterium whi...d structure of the bacteria can now be shown in th... of the pathogen and reveals previously unknown fe...
(Date:11/30/2009)... , The Editors of The Journal of Experimental Bi...in from Centre National de la Recherche Scientifiq...s is the winner of this year,s JEB Outstanding P...f an outstanding achievement and is intended to en...e JEB Editor-in-Chief, and adds that ,we truly a...
(Date:11/30/2009)... , A major obstacle to HIV research is the virus,...ning that scientists, traditional tools, like the ...tion. Now, a team of researchers writing in BioMed...ade an ingenious assault on this problem by creati...without being infected with HIV. , George Kassio...
Breaking Biology News(10 mins):Scientists gain new understanding of disease-causing bacteria 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4A reductionist approach to HIV research 2Lack of Insurance to Blame for Almost 45 000 Deaths 3A Study 57560 1Lack of Insurance to Blame for Almost 45 000 Deaths 3A Study 57560 2Lack of Insurance to Blame for Almost 45 000 Deaths 3A Study 57560 3Rare genetic disease successfully reversed using stem cell transplantation 9972 1Rare genetic disease successfully reversed using stem cell transplantation 9972 2Rare genetic disease successfully reversed using stem cell transplantation 9972 3Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO ESMO on September 22 2009 14130 1Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO ESMO on September 22 2009 14130 2Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO ESMO on September 22 2009 14130 3
...scovered female pelvis is changing minds about the...tus, and consequently revising notions about how s...not far from the site that yielded the 3.2 million...arensi "Lucy," the pelvis indicates that Homo erec... ago, had a larger birth canal than originally sus...
... how life started remains a major challenge for sc...COST ,Frontiers of Science, conference in Sicily i... to the problem. The first applies complex systems... The second involves studying Mars, which may yiel...fe evolved. , Gnter Von Kiedrowski, of Ruhr Unive...
...pe to gain a greater understanding of disease and ...l map the expression of genes that control develop...stitute at the University of Edinburgh, in collabo...), University College London, University of Bath a...hree dimensional images of chicks taken during the...
Other Biology News:Complex systems and Mars missions help understand how life began 2Complex systems and Mars missions help understand how life began 3Chicks to give scientists clearer picture of fetal development 2
... The new ArraySlide 96 chamber fits one microarray...faces for multiple simultaneous protein, gene expr...r systems, this device utilizes a compression fit ...adhesives. The chamber itself is made from a durab...
...lexing platform that uses advanced microarray tech...ence detection and pharmacogenetics applications. ...ied to an open and flexible electronic microarray,... all tests sites have been utilized. This open sys...
Rat siTrio from B-Bridge International
Phage Display cDNA Library Screening Kit from Spring Bioscience
Biology Products: